Caris Life Sciences is set to launch its multi-cancer early detection (MCED) assay, Caris Detect, in the first half of 2026, through a partnership with Everlywell, leveraging whole genome sequencing for early cancer screening.
Roche has entered the next-generation sequencing market with its new Axelios platform, aiming to compete with Illumina and targeting a commercial launch in summer 2026.
Anthropic has initiated an internal drug discovery program under Claude Science, focusing on neglected diseases and offering AI tools to accelerate biopharmaceutical R&D.
The broader life sciences sector is seeing intensifying competition in sequencing hardware and AI-driven drug discovery, reflecting a strategic shift toward precision medicine and AI-enabled platforms.
Sources:
Caris Life Sciences Reports Fourth Quarter and Full Year 2025 ...
Caris Partners with Everlywell to Launch MCED Assay, Caris Detect
Anthropic launches AI drug discovery program, Claude Science
The Dawn of the Axelios Era: Roche's Strategic Advance in Next ...
Roche takes aim at Illumina's dominance with new gene sequencing ...
Roche takes on Illumina with new NGS system | MedTech Dive
Anthropic Launches Claude Science, Initiates Drug Discovery ...
Caris Life Sciences Announces New Study Demonstrating the ...
Anthropic Just Shipped Claude Science and Stepped Into Drug ...